Business Information
The company's principal activity is to discover, develop and commercialize therapeutic protein-based products for the treatment of human diseases. The company has generated proprietary product candidates and commercializes them through internal development, collaborations with biopharmaceutical partners or out-licensing of patents. The company has developed five recombinant protein products marketed by other companies from which it derives royalties. The products are novolin(R), novorapid(R), novoseven(R), regranex(R), glucagen(R) and cleactor(tm). The products are marketed by novo nordisk, ortho-mcneil pharmaceuticals, inc. And eisai co., ltd. The company has also out-licensed two products to third parties in return for milestone payments and royalties.
|
|
Name |
Title
|
Email
|
| Bruce Carter | Chmn., CEO, Pres. | N/A | | Darren Hamby | Sr. VP - Human Resources | N/A | | Douglas Williams | Chief Scientific Officer, Exec. VP | N/A | | James Johnson | Exec. VP, CFO, Treasurer | N/A | | Michael Dwyer | Sr. VP - Sales, Marketing | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 25,380 | (130,002) | | 2005 | 42,909 | (78,027) | | 2004 | 35,694 | (88,756)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
